Inhibrx Secures $500M Credit Facility Expansion with Oxford Finance
Event summary
- Inhibrx amended its loan agreement with Oxford Finance, expanding the total facility to $500M.
- $100M was funded immediately under Term C Loan, with an additional $225M available under Term D Loan.
- Company issued warrants for 21,457 shares at a strike price of $93.21 per share as part of the deal.
- Inhibrx had previously drawn $175M under the original credit facility.
The big picture
This expanded credit facility provides Inhibrx with significant financial runway, allowing it to maintain aggressive clinical development timelines. The move underscores continued investor confidence in the company's pipeline despite broader market uncertainties in biotech financing. With $500M now available, Inhibrx gains strategic flexibility to pursue multiple high-value programs simultaneously.
What we're watching
- Execution Risk
- How Inhibrx will deploy the additional capital to advance its clinical pipeline, particularly ozekibart and INBRX-106.
- Market Dynamics
- Whether the expanded credit facility reflects broader investor confidence in biopharmaceutical financing amid volatile market conditions.
- Strategic Flexibility
- The pace at which Inhibrx can leverage this financial boost to accelerate key data readouts and maintain momentum in its programs.